CAMP4 Therapeutics Corporation Common StockCAMP
CAMP
About: Camp4 Therapeutics Corp is a clinical-stage biopharmaceutical company pioneering the discovery and development of regulatory RNA-based therapeutics to upregulate gene expression and restore healthy protein levels to treat various genetic diseases. It focuses on genetic diseases of the central nervous system and liver. The group's pipeline products are CMP-CPS-001 and CMP-SYNGAP.
–
Funds holding %
of 6,809 funds
0
Analysts bullish %
of 3 analysts
Fund manager confidence
Research analyst outlook
3 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$17
227%
upside
Avg. target
$19.33
272%
upside
High target
$23
342%
upside
3 analyst ratings
3 positive
100%
0 neutral
0%
0 negative
0%
Leerink Partners Mani Foroohar 38% 1-year accuracy 6 / 16 met price target | 227%upside $17 | Outperform Initiated | 5 Nov 2024 |
JP Morgan Eric Joseph 48% 1-year accuracy 14 / 29 met price target | 342%upside $23 | Overweight Initiated | 5 Nov 2024 |
Piper Sandler Edward Tenthoff 23% 1-year accuracy 10 / 43 met price target | 246%upside $18 | Overweight Initiated | 5 Nov 2024 |
Financial journalist opinion
Neutral
GlobeNewsWire
3 weeks ago
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference
CAMBRIDGE, Mass., Dec. 02, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced that management will present and be available for one-on-one meetings at the Piper Sandler 36th Annual Healthcare Conference to be held at the Lotte New York Palace Hotel in New York City December 3rd – 5th, 2024.
Neutral
GlobeNewsWire
1 month ago
CAMP4 Reports Third Quarter 2024 Financial Results
- Completed Initial Public Offering (IPO) of common stock, raising gross proceeds of $82.1M- Single Ascending Dose (SAD) portion of Phase 1 study of CMP-CPS-001 completed; safety data anticipated in Q1 2025- Entered strategic research collaboration with BioMarin valued at over $370M
Positive
Benzinga
1 month ago
CAMP4 Analyst Highlights Rare Disease Platform Potential
In October, CAMP4 Therapeutics Corporation CAMP priced its initial public offering of 6.82 million at $11.00 per share, with approximately $75 million in gross proceeds.
Neutral
GlobeNewsWire
2 months ago
CAMP4 Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass., Oct. 10, 2024 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels across a range of genetic diseases, today announced the pricing of its initial public offering of 6,820,000 shares of its common stock at an initial public offering price of $11.00 per share. All of the shares are being offered by CAMP4. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be approximately $75.0 million. CAMP4's common stock is expected to begin trading on the Nasdaq Global Market on October 11, 2024, under the ticker symbol “CAMP”. The offering is expected to close on October 15, 2024, subject to the satisfaction of customary closing conditions. In addition, CAMP4 has granted the underwriters a 30-day option to purchase up to an additional 1,023,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.
Positive
Seeking Alpha
2 months ago
Camp4 Therapeutics Targets IPO On Early Positive Results
Camp4 Therapeutics is seeking $75 million in an IPO to fund the advancement of its clinical-stage biopharma programs targeting genetic disorders. CAMP's lead candidate, CMP-CPS-001, has shown positive Phase 1 safety results for treating urea cycle disorders, with no concerning safety trends observed. The urea cycle disorders market is moderate in size, with a low expected growth rate, but Camp4 aims to broaden into larger markets.
Neutral
GlobeNewsWire
2 months ago
CalAmp Industrial IoT Gateway Named an OEM Off-Highway 2024 Top New Product Award Recipient
CARLSBAD, Calif., Sept. 24, 2024 (GLOBE NEWSWIRE) -- OEM Off-Highway, the nationally recognized magazine serving product development teams for mobile OEMs globally, has selected the HMU-3640LB Industrial IoT Gateway as one of the favored new mobile on- and off-road equipment products of 2024.
Neutral
GlobeNewsWire
3 months ago
CalAmp Welcomes Thomas Ayers as General Manager of Edge Device Business
CARLSBAD, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- CalAmp Corp. (“CalAmp”), a telematics company that provides products and solutions that help organizations monitor, track and protect vital assets, is pleased to announce the appointment of Thomas Ayers as General Manager of its Edge Device business. In this role, Ayers will spearhead the growth and innovation of CalAmp's edge device portfolio, leveraging his extensive expertise in hardware development and leading-edge technology.
Neutral
GlobeNewsWire
4 months ago
CalAmp Launches Inventory Manager for Seamless Device Deployments
CARLSBAD, Calif., Aug. 06, 2024 (GLOBE NEWSWIRE) -- CalAmp, a global leader in telematics solutions, is excited to announce the launch of the new Inventory Manager feature. This feature is designed to reduce operational friction and streamline the device onboarding process by providing enhanced visibility and oversight of shipped products.
Neutral
GlobeNewsWire
4 months ago
Lynrock Lake Takes CalAmp Private
CalAmp successfully completed restructuring in less than 60 days Emerges as private company with enhanced liquidity to invest in innovation to support customers' evolving needs CARLSBAD, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- CalAmp, Inc. (“CalAmp”), a telematics company that provides products and solutions that help organizations monitor, track and protect vital assets, is pleased to announce that it is now a private company owned by Lynrock Lake Master Fund LP (“Lynrock Lake” or “Lynrock”), a fund managed by Lynrock Lake LP.
Neutral
GlobeNewsWire
5 months ago
CalAmp Announces Appointment of Paul Washicko as Senior Vice President of Product Management
IRVINE, Calif., July 09, 2024 (GLOBE NEWSWIRE) -- CalAmp, a telematics company that provides products and solutions that help organizations monitor, track and protect vital assets, today announced the appointment of Paul Washicko as the new Senior Vice President of Product Management. In his role, Washicko will lead an accomplished team across the company's telematics portfolio of hardware and software solutions, driving innovation and growth.
Charts implemented using Lightweight Charts™